Hank JA - Search Results

1

Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.

Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM. Weil-Hillman G, et al. Among authors: hank ja. J Immunother (1991). 1991 Aug;10(4):267-77. doi: 10.1097/00002371-199108000-00005. J Immunother (1991). 1991. PMID: 1834166

2

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Sosman JA, et al. Among authors: hank j. J Natl Cancer Inst. 1988 Mar 2;80(1):60-3. doi: 10.1093/jnci/80.1.60. J Natl Cancer Inst. 1988. PMID: 3257526

3

Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested.

Kaur I, de Jong J, Schell K, Hank J, Fisch P, Sondel PM. Kaur I, et al. Cell Immunol. 1994 Jun;156(1):54-61. doi: 10.1006/cimm.1994.1152. Cell Immunol. 1994. PMID: 8200042

4

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.

Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Bogner MP, et al. Among authors: hank ja. J Immunother (1991). 1992 Feb;11(2):111-8. J Immunother (1991). 1992. PMID: 1571333

5

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Weil-Hillman G, et al. Among authors: hank ja. Cancer Res. 1990 May 1;50(9):2683-91. Cancer Res. 1990. PMID: 1691679

6

Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

Sosman JA, Oettel KR, Smith SD, Hank JA, Fisch P, Sondel PM. Sosman JA, et al. Among authors: hank ja. Blood. 1990 May 15;75(10):2005-16. Blood. 1990. PMID: 1692492 Free article.

7

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Voss SD, et al. Among authors: hank ja. J Exp Med. 1990 Oct 1;172(4):1101-14. doi: 10.1084/jem.172.4.1101. J Exp Med. 1990. PMID: 1698909 Free PMC article.

8

Immunological effects of levamisole in vitro.

Schiller JH, Lindstrom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, Sondel P, Borden EC. Schiller JH, et al. Among authors: hank ja. J Immunother (1991). 1991 Oct;10(5):297-306. doi: 10.1097/00002371-199110000-00001. J Immunother (1991). 1991. PMID: 1790137

9

BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase.

Cannon A, Hank JA, Sondel PM. Cannon A, et al. Among authors: hank ja. Biotherapy. 1991;3(3):253-60. doi: 10.1007/BF02171689. Biotherapy. 1991. PMID: 1854594

10

Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, et al. Sosman JA, et al. Among authors: hank ja. Cancer Invest. 1991;9(1):35-48. doi: 10.3109/07357909109032798. Cancer Invest. 1991. PMID: 2012995 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

163 results

Search Page

Filters